创伤患者院前血管加压药输注的效用与结局:一项系统评价
主要结局为全因院内死亡、大量输血和创伤诱导凝血病。两项研究校正后无显著关联,两项显示显著关联,一项军事研究显示校正后生存显著更低(aOR 0.32,95%CI 0.18-0.56);一项研究显示与大量输血(aOR 4.97,95%CI 1.24-19.91)和创伤诱导凝血病(aOR 3.05,95%CI 1.58-5.90)显著相关。总体证据确定性极低,尚不能确立院前血管加压药在创伤出血性休克中的安全性或特定临床指征。
要点
- 成人创伤低血压或出血性休克风险患者中,院前血管加压药持续输注与仅标准治疗相比,校正后死亡关联在不同研究间不一致。
- 一项军事研究显示院前血管加压药与校正后生存显著更低相关(aOR 0.32,95%CI 0.18-0.56)。
- 一项研究显示院前血管加压药与大量输血使用显著相关(aOR 4.97,95%CI 1.24-19.91)。
- 同一项研究显示院前血管加压药与创伤诱导凝血病显著相关(aOR 3.05,95%CI 1.58-5.90)。
- 现有证据仅来自极低确定性回顾性观察数据,不能据此确立院前血管加压药的安全性及具体临床指征。
适用人群与场景
- 成人创伤患者,表现为低血压或有创伤性出血性休克(THS)风险,处于院前创伤管理阶段。
- 暴露组为接受院前血管加压药(PhVP)持续输注者,对照组为仅接受院前标准治疗者。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 两项研究校正后显示院前血管加压药与死亡无显著关联,另两项显示显著关联。
- 一项军事研究显示院前血管加压药与校正后生存显著更低相关(aOR 0.32,95%CI 0.18-0.56)。
- 一项研究显示院前血管加压药与大量输血使用显著相关(aOR 4.97,95%CI 1.24-19.91),与创伤诱导凝血病显著相关(aOR 3.05,95%CI 1.58-5.90)。
证据类型、等级与局限
- 证据类型为系统评价,纳入的研究均为回顾性观察性研究,原文结论为极低确定性证据。
- 局限性包括:仅纳入回顾性研究、各研究间暴露定义差异较大、无法排除混杂、原文未提及具体偏倚风险评估细节。
对床旁实践的改变
- 现有极低确定性证据不足以支持或反对成人创伤低血压或出血性休克风险患者在院前常规使用血管加压药持续输注。
- 院前决策仍应以标准创伤救治和尽快控制出血为核心,血管加压药的使用需个体化并认识到安全性尚未确立。
- 原文未提及适用或不适用人群的具体界定,不能据此扩大或缩小临床适用范围。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Traumatic hemorrhagic shock (THS) remains a leading cause of potentially preventable mortality in the prehospital setting. The role of prehospital vasopressors (PhVP) before definitive hemorrhage control during prehospital trauma management remains uncertain. We aimed to evaluate the utility and association between PhVP use and clinical outcomes in trauma patients presenting with hypotension or at risk of the THS. A systematic review of observational studies was conducted and studies were retrieved through MEDLINE/PubMed and CENTRAL databases search between 2015 and 2026. Studies participants were adult trauma patients with hypotension or at risk of THS receiving continuous infusion of PhVP compared with those who received prehospital standard care alone. Outcomes included all-cause in-hospital mortality, massive blood transfusion use, and trauma-induced coagulopathy (TIC). Risk of bias, study selection, and certainty of evidence were independently evaluated, followed by qualitative synthesis. Among 678 records identified, five retrospective studies (31 849 patients) were eligible. A total of 1443 patients received PhVP, with substantial variation in exposure across studies. Two studies reported no significant association between PhVP and mortality after adjustment, while another two showed a significant association. A military study revealed significantly lower adjusted survival [adjusted odds ratio (aOR): 0.32, 95% confidence interval (CI): 0.18-0.56]. One study showed a significant association between PhVP and massive blood transfusion use (aOR: 4.97, 95% CI: 1.24-19.91) and TIC (aOR: 3.05, 95% CI: 1.58-5.90). Current evidence on the utility and outcomes of PhVP in trauma is limited to very low-certainty observational data. Only one study showed a significant association between PhVP use and increased mortality after adjustment. Prospective studies are required to establish safety and specific clinical indications.
参考来源
- El-Menyar A, Spencer Netto F, Al-Hassani I, et al. Utility and outcomes of prehospital vasopressors infusion in trauma patients: a systematic review. Eur J Emerg Med. 2026. PMID: 42808211. doi:10.1097/MEJ.0000000000001379
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。